Explore

Trendline Trendline
Cellares and ProTgen Partner to Automate T-Cell Therapy Manufacturing for Blood Cancer

Cellares and ProTgen Partner to Automate T-Cell Therapy Manufacturing for Blood Cancer

Cellares and ProTgen Partner to Automate T-Cell Therapy Manufacturing for Blood Cancer
Trendline Trendline
AIRNA Unveils Promising Preclinical Data on RNA-Editing Therapeutics

AIRNA Unveils Promising Preclinical Data on RNA-Editing Therapeutics

AIRNA Unveils Promising Preclinical Data on RNA-Editing Therapeutics
Trendline Trendline
Dual-Ligase Strategy Enhances Targeted Protein Degradation in Cancer Therapy

Dual-Ligase Strategy Enhances Targeted Protein Degradation in Cancer Therapy

Dual-Ligase Strategy Enhances Targeted Protein Degradation in Cancer Therapy
Trendline Trendline
JCR Pharmaceuticals to Showcase Gene Therapy Innovations at ASGCT Meeting in Boston

JCR Pharmaceuticals to Showcase Gene Therapy Innovations at ASGCT Meeting in Boston

JCR Pharmaceuticals to Showcase Gene Therapy Innovations at ASGCT Meeting in Boston
Trendline Trendline
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development
Trendline Trendline
Incyte to Present Key Hematology and Oncology Data at EHA 2026 Congress

Incyte to Present Key Hematology and Oncology Data at EHA 2026 Congress

Incyte to Present Key Hematology and Oncology Data at EHA 2026 Congress
Trendline Trendline
Hiteck Pharmaceutical and LexBio Unveil HT016 VAV1 Molecular Glue Degrader at AAI 2026

Hiteck Pharmaceutical and LexBio Unveil HT016 VAV1 Molecular Glue Degrader at AAI 2026

Hiteck Pharmaceutical and LexBio Unveil HT016 VAV1 Molecular Glue Degrader at AAI 2026
Trendline Trendline
AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials
Trendline Trendline
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Therapy

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Therapy

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Therapy
Trendline Trendline
Forge Biologics to Present Gene Therapy Advancements at ASGCT Annual Meeting

Forge Biologics to Present Gene Therapy Advancements at ASGCT Annual Meeting

Forge Biologics to Present Gene Therapy Advancements at ASGCT Annual Meeting
Trendline Trendline
BeOne Medicines Honored as 'Outstanding Global Oncology Company' for Advancements in Cancer Therapies

BeOne Medicines Honored as 'Outstanding Global Oncology Company' for Advancements in Cancer Therapies

BeOne Medicines Honored as 'Outstanding Global Oncology Company' for Advancements in Cancer Therapies
Trendline Trendline
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy to Advance AI-Driven Treatment

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy to Advance AI-Driven Treatment

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy to Advance AI-Driven Treatment